Evidence map›Paper›PMID 38537257›Full record

Observational studyInflammatory bowel diseases2025

Crohn's Disease Phenotypes and Associations With Comorbidities, Surgery Risk, Medications and Nonmedication Approaches: The MAGIC in IMAGINE Study.

Charles N Bernstein, Remo Panaccione, Zoann Nugent, Deborah A Marshall, Gilaad G Kaplan, Stephen Vanner, Levinus A Dieleman, Lesley A Graff, Anthony Otley, Jennifer Jones and 9 more

Abstract readMulticenter StudyObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Inflammatory bowel diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. STRIDE-II treatment target achievement in inflammatory bowel disease: a cross-sectional study from a tertiary IBD centre in the United Arab Emirates.Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Nutrients · 2024
    Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Charles N BernsteinDepartment of Internal Medicine, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Manitoba, Canada.ORCID 0000-0001-8041-3574
Remo PanaccioneDivision of Gastroenterology and Hepatology, Departments of Medicine, University of Calgary, Calgary, Alberta, Canada.ORCID 0000-0002-5247-940X
Zoann NugentDepartment of Internal Medicine, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Manitoba, Canada.
Deborah A MarshallDepartments of Community Health Sciences, University of Calgary, Calgary, Alberta, Canada.ORCID 0000-0002-8467-8008
Gilaad G KaplanDivision of Gastroenterology and Hepatology, Departments of Medicine, University of Calgary, Calgary, Alberta, Canada.
Stephen VannerQueens University, Kingston, Ontario, Canada.
Levinus A DielemanDepartment of Medicine, University of Alberta, Edmonton, Alberta, Canada.
Lesley A GraffUniversity of Manitoba Inflammatory Bowel Disease Clinical and Research Centre, Winnipeg, Canada.
Anthony OtleyDepartment of Pediatrics, Dalhousie University, Halifax, Nova Scotia, Canada.
Jennifer JonesDepartment of Internal Medicine, Dalhousie University, Halifax, Nova Scotia, Canada.
Michelle BuresiDivision of Gastroenterology and Hepatology, Departments of Medicine, University of Calgary, Calgary, Alberta, Canada.
Sanjay MurthyDepartment of Medicine, University of Ottawa, Ottawa, Ontario, Canada.
Mark BorgaonkarDepartment of Medicine, Memorial University, St Johns, Newfoundland, Canada.
Brian BresslerDepartment of Medicine, University of British Columbia, Vancouver, BC, Canada.
Alain BittonDepartment of Medicine, McGill University, Montreal, Quebec, Canada.
Kenneth CroitoruDepartment of Medicine, University of Toronto, Toronto, Ontario, Canada.
Sacha SidaniDepartment of Medicine, University of Montreal, Montreal, Quebec, Canada.
Aida FernandesDepartment of Medicine, McMaster University, Hamilton, Ontario, Canada.
Paul MoayyediDepartment of Medicine, McMaster University, Hamilton, Ontario, Canada.ORCID 0000-0002-3616-9292

Funding

Alberta InnovatesAllergan IncorporatedCanadian Institute of Health Research RN279389-35803Crohn's and Colitis CanadaDalhousie UniversityMcMaster UniversityMontreal Heart Institute Research CentreQueen's UniversityResearch ManitobaTakeda Pharmaceutical CompanyUniversity of Calgary, University of Alberta
6 · The paper itself

Abstract

backgroundWe aimed to establish a cohort of persons with Crohn's disease (CD) enrolled from 14 Canadian centers to describe the contemporary presentation of CD in Canada.

methodsAll enrollees were at least 18 years old and underwent chart review for phenotype documentation by Montreal Classification at time of enrollment, comorbidities, inflammatory bowel disease (IBD) and other surgeries, and use IBD and other therapies.

resultsOf 2112 adults, 59% were female, and the mean age was 44.1 (+/-14.9SD) years. The phenotype distribution was B1 = 50.4%, B2 = 22.4%, B3 = 17.3%, and missing information = 9.9%. Perineal disease was present in 14.2%. Pertaining to disease location, 35.2% of patients had disease in L1, 16.8% in L2, 48% in L3, and 0.4% in L4. There was no difference in phenotype by gender, anxiety score, depression score. Disease duration was significantly different depending on disease behavior type (B1 = 12.2 ± 10.1; B2 = 19.4 ± 12.9; B3 = 18.9 ± 11.8, P < .0001). Isolated colonic disease was much less likely to be fibrostenotic or penetrating than inflammatory disease. Penetrating disease was more likely to be associated with ileocolonic location than other locations. Perineal disease was most commonly seen in persons with B3 disease behavior (24%) than other behaviors (11% B1; 20% B2 disease, P < .0001) and more likely to be seen in ileocolonic disease (L3;19%) vs L2 (17%) and L1 (11%; P < .0001). Surgery related to IBD occurred across each behavior types at the following rates: B1 = 23%, B2 = 64%, and B3 = 74%. Inflammatory bowel disease-related surgery rates by location of disease were L1 = 48%, L2 = 21%, and L3 = 51%.

conclusionsIn exploring this large contemporary CD cohort we have determined that inflammatory disease is the main CD phenotype in Canada and that CD-related surgery remains very common.

Indexed as

ComorbidityCrohn DiseasePhenotypeAdultCanadaCohort StudiesFemaleHumansMaleMiddle AgedRisk Factorscohort studyCrohn’s diseasephenotypesurgery

Identifiers

PMID38537257
PMCPMC11700885

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.